Merck

Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.

Journal of immunology research (2015-03-31)
S D Dowall, V A Graham, K Corbin-Lickfett, C Empig, K Schlunegger, C B Bruce, L Easterbrook, R Hewson
RESUMEN

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Hexane, HPLC Plus, for HPLC, GC, and residue analysis, ≥95%
Supelco
Hexane, suitable for HPLC, ≥95%
Sigma-Aldrich
Hexane, anhydrous, 95%
Supelco
Hexane, analytical standard
Sigma-Aldrich
Hexane, puriss. p.a., ACS reagent, ≥99.0% (GC)
Sigma-Aldrich
Hexane, suitable for HPLC, ≥95%
Sigma-Aldrich
Hexane, Laboratory Reagent, ≥95%
Sigma-Aldrich
Hexane, ReagentPlus®, ≥99%
Sigma-Aldrich
Hexane, suitable for HPLC, ≥97.0% (GC)
Sigma-Aldrich
Hexane, HPLC Plus, for HPLC, GC, and residue analysis, ≥95%
Sigma-Aldrich
Hexane, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99% (GC)